Bispecific ADCs are seen as the next generation of ADC development and continue to be the focus of high-value dealmaking.
Amid this probe, experts point to the importance of airtight AI governance when implementing the technology in high-risk contexts.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Industry partnership will determine the success of the transition to low-GWP pMDIs
TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Keeping pace with generative AI in pharmaceutical and healthcare organisations